Business
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout and recommended Phase 2 doses
About this update from Genfit Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFIT","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"GENFIT’s CCA Phase 1b study progressing as planned:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint ","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1b data readout and recommended Phase 2 doses remain on track for 1H26","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":183,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":523,"olType":false},{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone payment from Ipsen under the companies’ licensing agreement.","length":475,"tagName":"p"},{"type":"text","content":"The commercial success of Iqirvo® in 2025 underscores the strength of our partnership with Ipsen and exceeded our initial expectations with first-year net sales reaching US$208M. This performance activated a US$20M milestone payment ahead of plan, reinforcing GENFIT’s financial position. This momentum also led to the receipt of an additional €30M tranche under GENFIT’s royalty‑financing agreement with HCRx, enhancing financial flexibility in a non-dilutive way.","length":465,"tagName":"p"},{"type":"text","content":"In parallel, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial in primary sclerosing cholangitis (PSC), addressing a significant unmet medical need, as no approved therapies currently exist for this severe and progressive disease. PSC represents a substan...